This confirms that the effects observed in the basal breast cancer xenografts are not due to off-target effects of the PERK inhibitor, as luminal cells—unlike basal cells—do not constitutively activate PERK and do not significantly respond to PERK inhibition. This evidence concerns the gene EIF2AK3 and breast cancer.